News

New research shows that mental health, life quality, and symptoms of eczema may all be improved through self-compassion and online mindfulness training that is both scalable and accessible to many.

An analysis of data from the TEDDY study suggests increased levels of moderate to vigorous physical activity could reduce risk of progression to type 1 diabetes in multiple islet autoantibody-positive children.

New data indicates an association between cardiovascular risk factors and psoriasis disease activity, shedding light on potential ways to identify and help those at risk for future heart issues.

A new study suggests ChatGPT may not provide substantial assistance in preparing for board certification at this time.

An analysis of data from nearly 100 adults with type 1 diabetes details associations between chronotypes and improved well-being in people with diabetes.

In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape.

New research shows that fall death rates for adults over 65 increased in both rate and number since 1999, indicating the necessity of more work toward fall prevention and reducing fall-related mortality.

The FDA approval comes with supporting data showing the ERT's non-inferiority to agalsidase beta in controlled eGFR decline.

A research letter highlighted coverage in The New York Times of a small study on oral minoxidil and this story’s connection with an immediate increase in the drug’s prescription rates.

Announced on May 10, 2023, topline results of the phase 2 dose-finding trial for BI 456906 suggests use was associated with reductions in body weight of up to 14.9% during the 46-week study.

A phase 3 trial comparing QL1206, a denosumab biosimilar, to the reference agent has returned results demonstrating the efficacy, safety, and pharmacokinetic equivalency of the biosimilar to the reference agent.

Bryn Pharma is planning to submit the New Drug Application for Utuly this year and expects to receive approval early next year.

Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.

The sensitivity for colorectal cancer detection of the blood-based test was 83%, meeting the co-primary sensitivity endpoint.

The lowest screening completion rate was in the colonoscopy invitation group at 14.5% and the patients offered a choice were more likely to complete screening of any kind, compared to either group of patients offered only 1 screening modality.

Retrospective data suggest a treat-and-extend regimen using brolucizumab is effective for improving outcomes in eyes with exudative AMD refractory to aflibercept.

The mean number of required reinterventions was significantly lower in the patients who received a direct endoscopic necrosectomy at index session when compared with patients who received the step-up treatment approach.

There was a significant reduction in severity score for diarrhea, constipation, abdominal pain, epigastric pain, bloating, vomiting, and acid reflux in participants who reported digestive problem improvements followed by SIM01 treatment.

Based on data presented at ARVO 2023, Parikh discusses how anti-VEGF biosimilars may increase both patient and overall healthcare costs.

Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.

The long-term extension SENSCIS-ON trial shows patients receiving nintedanib over 3 years were not at significantly greater risk of serious adverse events or outcomes.

Pooling data from the TODAY and SEARCH studies, new research offers an overview of the challenges in access to care and outcomes among adolescents with type 1 and type 2 diabetes

New data suggests that anti-IL-17A biologics including ixekizumab showed strong self-reported results in signs and symptoms for psoriasis patients.

Pending FDA approval, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration and diabetic macular edema.

Announced just more than a year after AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular death and HF hospitalizations for dapagliflozin based on results of the phase 3 DELIVER trial.

New data on using narrowband-UVB therapy for chronic plaque psoriasis found that the body’s lower limbs were the most difficult to treat, though excellent responses were still reported.

Results showed standardized reporting was frequently used in low-dose computed tomography lung screening, with the majority of instances being considered reportable to the clinician and requiring follow-up.

RBX2660 can be administered through a colonoscopy or rectally.

The approval, granted to Eyenovia, Inc, represents the first-approved fixed-dose combination of tropicamide and phenylephrine for inducing mydriasis for diagnostic procedures and short-term pupil dilation.